Intermune, Inc.

Alios Biopharma, Inc.

Aligos Therapeutics, Inc.

Vertex Pharmaceuticals, Inc.

Other

Katholieke Universiteit Leuven

Ribozyme Pharmaceuticals, Incorporated

Vladimir Serebryany

Leonid Beigelman

Scott D Seiwert

Karl Kossen

Lawrence M Blatt

Ramachandran Radhakrishnan

Jyanwei Liu

Tao Hu

Donald Ruhrmund

Luca Francesco Mario Raveglia

Stefania Vallese

Ivana Bianchi

David Bernard Smith

Luigi Anzalone

Antitsa Dimitrova Stoycheva

Sandrine Vendeville

Shereen Ibrahim

Pierre Jean-Marie Bernard Raboisson

Brad Owen Buckman

Koen Vandyck

Alexander Karpeisky

Young Chun Jung

Dorothée Alice Marie-Eve Bardiot

Williamson Ziegler Bradford

David Sweedler

Luca Francesco Raveglia

Peter Haeberli

Peter Jamison Rose

Arnaud Didier Marie Marchand

Sandro Boland

Cavan McKeon Bligh

Steven B Porter

Jamison Rose

Cavan McKeon

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Anti-viral compounds

Pyrrole compounds

Disclosed herein are methods of preparing a nucleoside analog, Compound (I): or a pharmaceutically acceptable salt thereof, which is useful in treating diseases and/or conditions such as viral infections, and intermediates thereof.

Methods of preparing substituted nucleoside analogs

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. Mederski et al., Tetrahedron (1999), 55(44), 12757-12770.* Azuma et al., 'A placebo control and double blind phase II clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis in Japan', Am J Respir Crit Care Med., 165:A729 (2002). Badger, et al., 'Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function', J. Pharmacol. Exp. Ther. 279:1453-61 (1996).

Compounds and methods for treating inflammatory and fibrotic disorders

Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

Method of modulating stress-activated protein kinase system

Disclosed herein are methods of preparing a nucleoside analog (I) by a reaction that includes an intermediate (GG):  Nucleoside analog (I) is useful in treating diseases and/or conditions such as viral infections.

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.

Methods of preparing substituted nucleotide analogs

The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

Growing community of inventors

Burlingame, CA, United States of America

Vladimir Serebryany